Novo Nordisk will seek FDA approval to dramatically expand the number of patients eligible for the shots.
People taking Ozempic in a multinational trial experienced a 24 percent reduction in risk of death from cardiovascular and kidney disease compared with those who received a placebo. The active compound in the best-selling drug Ozempic markedly lowers the risk of complications from chronic kidney disease, according to a multiyear study published Friday — a finding that could dramatically expand the pool of patients eligible for the injections.
Funded by Ozempic maker Novo Nordisk and involving 3,533 patients around the world, a study released in Stockholm at the European Renal Association meeting and published in the New England Journal of Medicine found that patients receiving semaglutide — the key ingredient — experienced a 24 percent reduction in risk of death from cardiovascular and kidney disease compared with those who received a placebo.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bernie Sanders Urges Ozempic Maker Novo Nordisk To Be Fair Over ‘Outrageously Expensive’ U.S. Drug PricesRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Novo Nordisk To Slash Prices On Buzzy Drugs Ozempic and WegovyScience and Technology News and Videos
Read more »
Novo Nordisk executive responds to criticisms of Ozempic cost, availabilityNegelle Morris, Novo Nordisk's senior vice president and head of U.S. cardiometabolic sales, spoke exclusively with ABC News.
Read more »
Novo Nordisk announces $6B investment in Ozempic, Wegovy amid shortagesNovo Nordisk's Negelle Morris spoke exclusively with ABC News.
Read more »
Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug FrenzyI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Read more »
Ozempic Maker Novo Nordisk Beats Profit Forecasts Amid Weight Loss Drug FrenzyI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Read more »